Brunswick further strengthens global Healthcare and Life Sciences capabilities.
October 16, 2023 – Brunswick Group, the world’s leading critical issues advisory firm, today announced that Carri Duncan has joined the firm as a Partner, based in Berlin.
Carri has worked for much of her distinguished career in the public and private capital markets, with a focus on the healthcare and life sciences sector. Most recently, Carri ran her own consultancy, sourcing healthcare investment opportunities for private capital firms and global family foundations, as well as providing strategic advice on reputation and stakeholder management to healthcare and life sciences companies. Her prior experience includes serving as a senior Investor Relations professional at Bayer, as a consultant at Egon Zehnder, as a buy-side equity analyst at Credit Suisse and in investment banking roles at Sal Oppenheim-Macquarie.
At Brunswick, Carri will further strengthen the firm’s global Healthcare and Life Sciences sector, which is growing around the world and advising clients on a wide range of critical financial, political and social issues.
Neal Wolin, Chief Executive Officer, said: "Carri brings a wealth of experience relevant to our clients across the healthcare and life sciences sector. She has a deep understanding of the issues affecting companies in the industry and the stakeholders that matter. I am delighted she is joining Brunswick.”
On joining Brunswick, Carri Duncan said: "Healthcare systems around the world are increasingly facing complex regulatory landscapes, rapid scientific and technological changes and rising costs. With Brunswick's global perspective and focus on critical issues and stakeholders, I am excited to partner with this team and jointly enhance the value we deliver to our clients worldwide."
About Carri Duncan:
Carri joins Brunswick from Karaktero, a consultancy she co-founded, which provides advisory services on strategy, communications, organizational design and capital markets effectiveness. At Bayer AG, Carri served as VP Investor Relations. She also spearheaded Bayer’s first global AI initiative across its Healthcare divisions. At Egon Zehnder, she advised leading healthcare companies on talent, conducting management assessments and making strategic placements. After leaving academic research at ETH-Zurich and Novartis, Carri began her business career at Credit Suisse, where she was part of the team that established buy-side Biotech, paving the way for her subsequent roles in the healthcare sector. She is regularly invited to speak by leading global institutions seeking insights into the healthcare sector.
Carri earned a bachelor’s degree from Wayne State University, a M.S. in Genetics from the US Dept. of Energy’s PRL at Michigan State University and a PhD in Neuroscience from ETH-Zurich.
About Brunswick Group
Brunswick is a strategic advisory firm focused on critical issues and critical stakeholders. Our purpose is to help our clients play their role in the world successfully. We advise on critical issues and critical stakeholders at the center of business, politics and society, and help our clients – the leaders of large, complex organizations – understand and navigate these interconnected worlds. Brunswick is one firm globally, operating as a single profit center. This allows us to respond seamlessly and effectively to clients’ needs wherever they are in the world.
For more information, visit: www.brunswickgroup.com
Chris Buscombe: [email protected]